Moderna Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Moderna kazanç ve gelirin sırasıyla yıllık 18.1% ve 7.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 17.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -24.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

18.1%

Kazanç büyüme oranı

17.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.3%
Gelir büyüme oranı	7.4%
Gelecekteki özkaynak getirisi	-24.6%
Analist kapsamı	Good
Son güncelleme	11 Nov 2024

Gelecekteki son büyüme güncellemeleri

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27

Recent updates

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Oct 22

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Oct 11

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27

Moderna: Counting On Pipeline Too Much

Feb 23

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:MRNA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,918	-2,580	-2,324	-1,560	18
12/31/2025	3,086	-3,392	-3,149	-2,600	23
12/31/2024	3,304	-3,481	-3,466	-2,732	21
9/30/2024	5,081	-2,224	-3,956	-3,207	N/A
6/30/2024	5,050	-5,867	-3,979	-3,241	N/A
3/31/2024	5,153	-5,968	-3,672	-2,882	N/A
12/31/2023	6,848	-4,714	-3,825	-3,118	N/A
9/30/2023	9,121	-3,466	-2,657	-2,078	N/A
6/30/2023	10,654	1,207	-754	-226	N/A
3/31/2023	15,059	4,784	612	993	N/A
12/31/2022	19,263	8,362	4,581	4,981	N/A
9/30/2022	21,390	11,765	6,201	6,629	N/A
6/30/2022	22,995	14,055	9,215	9,653	N/A
3/31/2022	22,600	14,638	13,031	13,412	N/A
12/31/2021	18,471	12,202	13,336	13,620	N/A
9/30/2021	11,831	7,061	11,386	11,574	N/A
6/30/2021	7,019	3,495	9,083	9,191	N/A
3/31/2021	2,732	598	5,007	5,104	N/A
12/31/2020	803	-747	1,959	2,027	N/A
9/30/2020	246	-597	613	664	N/A
6/30/2020	106	-488	-374	-336	N/A
3/31/2020	52	-505	-451	-421	N/A
12/31/2019	60	-514	-491	-459	N/A
9/30/2019	82	-535	-489	-451	N/A
6/30/2019	106	-499	-482	-424	N/A
3/31/2019	122	-459	-445	-364	N/A
12/31/2018	135	-402	-437	-331	N/A
9/30/2018	192	-299	-447	-343	N/A
6/30/2018	192	-280	N/A	-305	N/A
3/31/2018	199	-266	N/A	-350	N/A
12/31/2017	206	-270	N/A	-331	N/A
12/31/2016	108	-230	N/A	67	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MRNA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: MRNA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: MRNA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: MRNA şirketinin gelirinin (yıllık 7.4% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MRNA şirketinin gelirinin (yıllık 7.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MRNA 3 yıl içinde kârsız olması bekleniyor.

Moderna Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 7.0% to US$85.80

Price target decreased by 16% to US$105

Consensus revenue estimates fall by 21%

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Recent updates

Price target decreased by 7.0% to US$85.80

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna: Still Bullish View

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Price target decreased by 16% to US$105

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Consensus revenue estimates fall by 21%

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Moderna, Inc. Announces Board Changes

Co-Founder notifies of intention to sell stock

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna: Really Strong Competition

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Co-Founder notifies of intention to sell stock

Moment Of Truth Approaches For Moderna's RSV Vaccine

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

Moderna Q1: A Promising Pipeline Is Undervalued

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Moderna: Considering The Cancer Vaccine Angle

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna Continues To Build A Pipeline

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Co-Founder notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

President notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Moderna: Counting On Pipeline Too Much

Moderna, Inc., Annual General Meeting, May 06, 2024

Consensus EPS estimates fall by 12%

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin